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Foot-and-mouth disease virus (FMDV) causes a highly infectious and economically devastating 
disease of livestock. The FMDV genome is translated as a single polypeptide precursor that is 
cleaved into functional proteins predominantly by the highly conserved viral 3C protease, 
making this enzyme an attractive target for antiviral drugs. A peptide corresponding to an 
optimal substrate has been modified at the C-terminus, by the addition of a warhead, to produce 
irreversible inhibitors that react as Michael acceptors with the enzyme active site. Further 
investigation highlighted key structural determinants for inhibition, with a positively charged P2 
being particularly important for potency. 
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Foot-and-mouth-disease virus (FMDV) is the causative agent of a 
highly contagious disease of cloven-hoofed mammals and 
disease outbreaks have significant economic impact 1. It is 
generally associated with low levels of development and it has 
become enzootic in areas of Africa, Asia, South America and the 
Middle East. However, it also occurs sporadically in areas that 
are usually free of the disease, most notably recently in the 
United Kingdom in 2001 2 and 2007 3 and in Japan in 2010 4.  
Although use of FMDV vaccines has been successful in 
reducing the frequency of outbreaks 5, preventive vaccination is 
not practiced in the United States or Europe due to the 
restrictions it entails on international trade of animals and animal 
products and the inability to detect carriers in vaccinated 
populations 6. An additional hazard of vaccination is that FMDV 
vaccine production utilises live virus, which presents a 
containment risk. There is evidence that some FMD outbreaks 
have actually had a vaccine origin due to incomplete inactivation 
prior to formulation 7, or result from the escape of the virus from 
laboratory sources 8. These events highlight the need for more 
effective control methods and, in fact, vaccines that do not 
require infectious FMDV at any stage of their production are in 
development 9. An alternative strategy is the design of anti-
FMDV drugs. 
FMDV belongs to the Aphtovirus genus of the Picornaviridae 
family and has a small non-enveloped icosahedral capsid that 
contains a linear, positive sense RNA genome 10. This highly 
contagious viral family includes human rhinovirus (HRV), 
hepatitis A virus (HAV) and poliovirus (PV). The molecular 
basis of FMDV pathogenesis and the regulation of picornavirus 
gene expression have been reviewed 11 . A key step in viral 
replication is the cleavage of a single polyprotein to form the 
final mature structural and functional viral proteins. A total of 13 
cleavages are required, of which 10 are performed by one of the 
virally-encoded proteins, 3C protease (3Cpro). This makes the 
FMDV 3Cpro enzyme a potential drug target for preventing viral 
replication, with no known cellular homologues being found in 
susceptible hosts. The structures of 3Cpro enzymes from the 
related HRV 12, HAV 13 and PV 14 have been determined, and we 
have solved the structure of FMDV 3Cpro 15, which may assist 
this process. Structurally, the enzyme is found to be a 
chymotrypsin-like cysteine protease 13, 15a, 15c.  
Furthermore, FMDV 3Cpro is one of the most highly conserved 
proteins in the viral genome, being 76% identical in amino acid 
sequence across all serotypes 16, with the substrate-binding site 
being one of the most highly conserved features of the enzyme. 
Protease inhibitors may therefore have the advantage of being 
active against a range of different FMDV serotypes, in marked 
contrast to vaccines that are serotype-specific.  
The 3Cpro from HRV has been the subject of an extensive 
study to find inhibitors, with peptidic α,β-unsaturated esters 
being found to act as selective mechanism-based inhibitors 17. 
These inhibitors add a Michael acceptor warhead on to a short 
peptide that represents the preferred P-side substrate sequence for 
the enzyme (for an overview see 18). This route has led to some 
potent HRV 3Cpro inhibitors: Ruprintrivir (AG7088) is an 
irreversible inhibitor with low nM EC50 values 19. Although 
initial proof of concept was achieved 20, Rupintrivir did not 
significantly enhance recovery levels during a natural infection 
study and development was stopped 21. Nonetheless, structural 
aspects of Rupintrivir have been used in efforts to inhibit various 
3C-like viral cysteine proteases 22.  
These efforts have focused on the design of broad spectrum 
anitivirals based on the similarities between such viral proteases. 
For example the structural relationship between FMDV 3Cpro and 
HRV 3Cpro allows the potent inhibition of the former by 
Rupintrivir, designed for the latter 22c. In contrast, the work 
presented here uses structural information from our previous 
studies to design an inhibitor specific to FMDV 3Cpro. The 
optimal substrate for FMDV 3Cpro has the sequence APAKQ-
LLNFD, which corresponds to the VP1/2A junction of the viral 
polyprotein 15a, 15c. Of this sequence, the P4-P1 residues (PAKQ) 
are the most critical for selectivity. The concept is illustrated in 
Scheme 1, yielding compound 1 as a potential inhibitor. 
 
 
Scheme 1 FMDV 3Cpro P4–P1′ substrate sequence and the first FMDV 3Cpro 
inhibitor design (1). A tetrapeptide is modified on its N-terminus containing a 
Michael acceptor (MA) moiety, in this case an α,β-unsaturated ester, taking 
the P1′ position of the original substrate. 
 
Two different synthetic routes were used to make the 
inhibitors described in the present study, as illustrated below for 
the synthesis of inhibitor 1. In both cases, the unsaturated ester 
moiety was achieved by a Wittig or Horner-Wadsworth-Emmons 
(HWE) reaction and the peptide sequence through solid phase 
peptide synthesis (SPPS). In one route (Scheme 2), glutamine is 
loaded onto Wang resin and SPPS carried out. The aldehyde 2 is 
then achieved by reductive cleavage of the C-terminus of the 
peptide from the resin. An HWE reaction to form the Michael 
Acceptor 3, followed by deprotection of the side chains 
completes the synthesis. The other route (Scheme 3) utilises a 
Wittig reaction to pre-form a building block onto which the 
peptide sequence is subsequently assembled. A protected 
glutamic acid 4 was first modified on its C-terminus to provide 
the corresponding Michael acceptor 5.23 The acid can then be 
attached to resin and the peptide sequence added on as before. 
 
Scheme 2. Synthesis of Michael acceptor peptides (route A) 
Reagents and conditions: (i) 20% piperidine in DMF. (ii) DIPCDI, HOAt, 
FmocGln(Trt)OH. (iii) Ac20, Dipea. (iv) Fmoc SPPS. (v) LiAlH4 in THF, -30 
ºC. (vi) NaHMDS in THF, -78 ºC. (vii) TFA/H2O/TIS, 95:2.5:2.5. 6% yield. 
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Additionally, the N terminus of the peptide can be acetylated 




Scheme 3. Synthesis of Michael acceptor peptides (route B) 
Reagents and conditions: (i) DCC/DNAP, BnSH. (ii) Et3SiH, Pd/C. (iii) THF 
(iv) 10% TFA in DCM. (v) 20% piperidine in DMF. (vi) 
HOAt/HATU/DIPEA. (vii) Fmoc SPPS. (viii) TFA/H2O/TIS, 95:2.5:2.5. 37% 
yield. 
Both routes offer advantages and disadvantages. Route A is a 
more convenient way to generate a range of different warheads 
having the same peptide sequence. Route B is better suited to 
production of peptide variants of a particular Michael acceptor 
warhead. The latter route is also dependent on attaching the 
modified amino acid via the side chain; it is therefore useful for 
glutamine variants (as here) and with slight modification could 
yield asparagine, glutamate or aspartate sequences. A minor 
limitation of route B is that the warhead needs to be resistant to 
the peptide synthesis conditions (particularly the TFA cleavage). 
An advantage is that although this synthetic route is slightly 
longer than route A the overall yield is much higher (on average 
37% after 15 steps compared with 3-6% over 13 steps). 
To characterise the compounds synthesised were tested for 
their ability to inhibit recombinant FMDV 3Cpro in vitro in the 
presence of the previously described fluorogenic substrate 
DABCYL-APAKQ↓LLD(EDANS)FDLLK, where ↓ marks the 
position of the scissile bond 24 25.  
Initially, 4 analogues of the inhibitor were synthesized, 
corresponding to the various lengths of P-side peptide sequence 
(Table 1). It was found that sequences which included up to P5 
(6) or P4 (7) acted as potent inhibitors of the enzyme with 
apparent IC50 values in the sub-micromolar range; compound 8, 
which extends only to P3 was a significantly poorer inhibitor 
while compound 9, which extends only to the P2 position, is 
essentially inactive as an inhibitor. These data are consistent with 
the substrate specificity studies of FMDV 3Cpro, which show that 
sequence changes at P4, P2 and P1 result in marked loss of 
activity 15a, 15c. The presence or absence of a P5 residue was found 
to have little influence on activity in this assay. However, it is 
known that that residues with very different structures (Ala, Pro, 
Arg, Asp, Glu and Leu) are found among the naturally occurring 
cleavage sequences of FMDV 3Cpro at P5 26, suggesting that few 
if any specific interactions are made with this side chain. 
It should be noted that the assays in this study were performed 
at an enzyme concentration of 0.6 µM, which was necessary in 
order to determine the rate of substrate hydrolysis (the activity of 
this viral protease is far lower than typical digestive proteases, 
necessitating high enzyme concentrations for reliable assay data). 
As IC50 cannot be less than 50% enzyme concentration this sets a 
lower threshold for what can be observed in these assays. It is 
therefore possible that the measured IC50 values for the best 
inhibitors are underestimates of the potency at lower enzyme 
concentration. 
 
Table 1. Effect of peptide chain length on antiprotease 
activity against FMDV 3Cpro 
 
 
Compound -R IC50 (µM) 
6 Ac-Ala-Pro-Ala-Lys- 0.64 ± 0.08 
7 Ac-Pro-Ala-Lys- 0.68± 0.06 
8 Ac-Ala-Lys- 17± 0. 8 
9 Ac-Lys- > 600 
 
Initially, all compounds were N-acetylated. To examine the 
effect of N-terminal modification on inhibitory potency, 
analogues of compound 7 were synthesized (Table 2). 
Compounds 10, 11 and 12 were generated by capping the 
tetrapeptide with benzoyl, tosyl and benzyl respectively and 13 
by capping the tripeptide with benzoyl. Compound 1, which 
lacks the N-terminal acetylation, was found to be a poorer 
inhibitor than compound 7. This suggests that the presence of a 
charged N-terminus is sub-optimal for inhibition. The natural 
substrates for 3Cpro are extended polypeptides, which the N-
acylated version is expected to mimic more closely. All N-capped 
versions of compound 1 (7, 10, 11, 12) were found to have 
improved activity, reinforcing this view. The best inhibitor of the 
series has a benzoyl cap (12). A benzoyl cap is also found to 
improve inhibition when the P4 Pro residue is removed (13); this 
shorter peptide is more active than the corresponding acetylated 
version (8) although loss of the P4 Pro results in less potent 
inhibition overall. 
 
Table 2. Effect of N-terminal cap on antiprotease activity against FMDV 
3Cpro 
 
Compound -R IC50 (µM) 
1 H-Pro- 4.6 ± 0.03 
7 Ac-Pro- 0.68 ± 0.06 
10 Bz-Pro- 0.43 ± 0.03 
11 Tos-Pro- 1.6 ± 0.1 
12 Bn-Pro- 1.5 ± 0.1 
8 Ac- 17 ± 0.8 
13 Bz- 2.3 ± 0.3 
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In the co-crystal structure of the enzyme with a peptide 
substrate, the P5 position is mostly solvent exposed and lacks 
significant enzyme contacts15c, which is illustrated in Figure 1. 




Figure 1. The substrate binding pocket of FMDV 3Cpro 
The structure of a substrate peptide bound into the active site of 3Cpro, 
illustrating that the P5 residue is largely solvent exposed and that a P2 Lys 
residue makes interactions with the side chains of two Asp residues within the 
active site. 
 
The nature of the electron withdrawing group within the 
Michael acceptor warhead is known to modulate the potency of 
inhibitors of human rhinovirus 3Cpro 17. Inhibitors with three 
different EWGs were compared for inhibition potency, these 
being the ethyl ester (7), benzyl ester (14) and N-methoxy-N-
methyl carboxamide (15) analogues (Table 3). The most potent 
warhead was the α,β-unsaturated ethyl ester, as indeed was the 
case for the rhinovirus enzyme. The other two analogues tested 
were less potent, with the N-methoxy-N-methyl carboxamide 
having an IC50 value 100-fold higher than the ethyl ester. At 
present it is not clear why the ester group has such a large effect 
on activity but these results show that variation in this position 
does have a significant effect on potency. In particular, there is 
no structural information that could be used to explain these 
differences and it is likely that a more extensive set of variants 
would reveal more potent analogues. 
Table 3. Effect of Michael acceptor variation on antiprotease activity against 
FMDV 3Cpro 
 
Compound -R IC50 (µM) 
7 
 
0.68 ± 0.06 
14 
 
7.7 ± 0.7 
15 
 
66 ± 6 
 
We have previously shown that a lysine residue is preferred at 
the P2 position of FMDV 3Cpro substrates 15a. Substrates 
containing other positively charged residues (Orn and Arg) are 
also hydrolysed by the protease whereas the presence of neutral 
side chains at P2 (Thr and Nle) abrogated hydrolysis15c. The 
crystal structure of 3Cpro with bound peptide substrate reveals 
that the preference for a P2 Lys side chain is due to salt-bridge 
interactions with two aspartic acid residues (Asp144 and Asp146) 
in the flexible β-ribbon of the enzyme15c as shown in Figure 1. 
To examine the role of P2, a series of compounds containing a 
range of P2 substitutions was synthesised and compared to the P2 
lysine variant 7 (Table 4). These inhibitors include variants in 
which the positive charge was deleted, replaced by a negative 
charge or subtly relocated using other positively-charged 
analogues. In general, the P2 preference for the inhibitors mirrors 
that for substrates, with positively charged residues being greatly 
preferred. Lys is the optimal residue, but Arg is almost as potent 
and Orn and His also provide significant inhibition. In contrast, 
an anionic residue is deleterious to inhibition, 17 giving no 
inhibition even when at 500 µM. 
Table 4. Specificity of P2 sequence for antiprotease activity against FMDV 
3Cpro 
 
Compound P2 -R IC50 (µM) 
7 Lys  0.68 ± 0.06 
16 Gly  2800 ± 445 
17 Glu  NI
† 
18 Gln  53 ± 0.2 
19 Lys(Ac)  130 ± 12 
20 Orn  2.7 ± 0.1 
21 Dab  21 ± 0.8 
22 Arg 
 
0.84 ± 0.03 
23 nArg 
 
3.8 ± 0.1 
24 hArg 
 
1.2 ± 0.2 
25 His 
 
9.8 ± 0.3 
†NI = No inhibition observed at the highest inhibitor concentration tested 
(500 µM). 
To obtain evidence for the formation of an irreversible 
complex, compound 7 was incubated with the FMDV 3Cpro 
enzyme and the inhibited complex was analysed by electrospray 
mass spectroscopy. Mass analysis of FMDV 3Cpro revealed a 
mixture of species with molecular weights 23,106, 23,182 and 
23,258 Da. The expected molecular weight is 23,032 Da. We 
interpret these data as indicative of the presence of β-
mercaptoethanol adducts 27, where 1, 2 or 3 molecules of 
mercaptoethanol (76 Da) remain associated from the purification 
buffers. After incubation with compound 7, the most abundant 
peak in the mass spectrum corresponded to a mass of 23,640 Da. 
The addition of one molecule of inhibitor would increase the 
mass of the enzyme by 538 Da; the experimentally determined 
increase of 534 Da compared with the lowest mass found in the 
native enzyme is consistent with this, within the error limits of 
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the mass determination in this experiment (roughly ± 4 Da). It is 
therefore found that the inhibited enzyme shows the attachment 
of a single molecule of inhibitor, providing good evidence for the 
desired mode of inhibition. 
In summary, we have shown that peptidic analogues of an 
optimal 3Cpro cleavage sequence that contain a Michael acceptor 
warhead act as potent inhibitors of this enzyme. The mechanism 
of inhibition involves the formation of a covalent 1:1 complex 
with the enzyme, which we presume to be via reaction with the 
catalytic cysteine residue. Potent inhibition requires a four-
residue peptide sequence and a blocked N-terminus is preferred. 
Inhibition potency strongly mirrors substrate specificity, with a 
marked preference for a positively charged residue in the P2 
position. The nature of the EWG that forms part of the Michael 
acceptor also strongly influences reactivity, with an ethyl ester 
being the most potent of those tested. 
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